Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 52

Results For "disease"

2674 News Found

Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million
News | October 17, 2025

Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million

Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio


Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer
Clinical Trials | October 17, 2025

Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer

Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents


IOL Chemicals receives EDQM certificate for Pantoprazole Sodium Sesquihydrate Process-III
News | October 16, 2025

IOL Chemicals receives EDQM certificate for Pantoprazole Sodium Sesquihydrate Process-III

Pantoprazole sodium is a proton pump inhibitor reduces stomach acid


Merck KGaA  to acquire chromatography business of JSR Life Sciences
News | October 16, 2025

Merck KGaA to acquire chromatography business of JSR Life Sciences

Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions


Gilead and Kite to transform cancer care with new data at ESMO 2025
Clinical Trials | October 14, 2025

Gilead and Kite to transform cancer care with new data at ESMO 2025

The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy


Roche’s Elecsys pTau181 becomes first FDA-cleared blood test to rule out Alzheimer’s pathology in primary care
R&D | October 14, 2025

Roche’s Elecsys pTau181 becomes first FDA-cleared blood test to rule out Alzheimer’s pathology in primary care

New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency


Roche to present latest cancer care data at ESMO 2025
Clinical Trials | October 13, 2025

Roche to present latest cancer care data at ESMO 2025

Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant


AstraZeneca to unveil breakthrough cancer trial results at ESMO 2025
Clinical Trials | October 13, 2025

AstraZeneca to unveil breakthrough cancer trial results at ESMO 2025

The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types


Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio
News | October 12, 2025

Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases


Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
News | October 12, 2025

Novo Nordisk to acquire Akero Therapeutics for $5.2 billion

Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases